Exercise limitation in COPD: Mechanisms, assessment and treatment

European Respiratory Review

Volumn 13, Issue 89, 2004, Pages 35-39

  Magnussen, H ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Activity; Chronic obstructive pulmonary disease; Dyspnoea; Hyperinflation; Pulmonary rehabilitation; Tiotropium

Indexed keywords

BRONCHODILATING AGENT; TIOTROPIUM BROMIDE;

ACCELEROMETER; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DYSPNEA; EXERCISE; EXPIRATORY FLOW; HUMAN; LUNG FUNCTION; LUNG VOLUME;

EID: 2942746699     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Dykstra BJ, Scanlon PD, Kester MM, Beck KC, Enright PL. Lung volumes in 4,774 patients with obstructive lung disease. Chest 1999; 115: 68-74.
2. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD. Is spirometry useful? Chest 2000; 117: 42S-47S.
3. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770-777.
4. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med2001; 163: 1395-1399.
5. Borg G, Holmgren A, Lindblad I. Quantitative evaluation of chest pain. Acta Med Scand Suppl 1981; 644: 43-45.
6. O'Donnell DE, Lam MIU, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557-1565.
7. Wegner RE, Jorres RA, Kirsten DK, Magnussen H. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur RespirJ 1994; 7: 725-729.
8. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
9. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580-586.
10. Fletcher CM, Elmes PC, Fairbain AS. The significance of respiratory symptoms and diagnosis of chronic bronchitis in working population. BMJ 1959; 2: 257-266.
11. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42: 773-778.
12. Gross NJ. Extrapulmonary effects of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2001; 7: 84-92.
13. Mahler DA, Harver A, Schwartzstein RM, et al. Understanding dyspnoea in COPD: mechanisms, measurement and management. Eur Respir Rev 2002; 12: 82, 25-55.
14. Dyer CA, Singh SJ, Stockley RA, Sinclair AJ, Hill SL. The incremental shuttle walking test in elderly people with chronic airflow limitation. Thorax 2002; 57: 34-38.
15. Kirsten DK, Taube C, Lehnigk B, Jorres RA, Magnussen H. Exercise training improves recovery in patients with COPD after an acute exacerbation. Respir Med 1998; 92: 1191-1198.
16. Behnke M, Taube C, Kirsten D, et al. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir Med 2000; 94: 1184-1191.
17. Tudor-Locke CE, Myers AM. Challenges and opportunities for measuring physical activity in sedentary adults. Sports Med 2001; 31: 91-100.
18. Garrod R, Bestall JC, Paul EA, Wedzicha JA, Jones PW. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). Respir Med 2000; 94: 589-596.
19. Tudor-Locke C, Williams JE, Reis JP, Pluto D. Utility of pedometers for assessing physical activity: convergent validity. Sports Med 2002; 32: 795-808.
20. Steele BG, Holt L, Belza B, Ferris S, Lakshminaryan S, Buchner DM. Quantitating physical activity in COPD using a triaxial accelerometer. Chest 2000; 117: 1359-1367.
21. Lareau SC, Carrieri-Kohlman V, Janson-Bjerklie S, Roos PJ. Development and testing of the Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ). Heart Lung 1994; 23: 242-250.
22. Behnke M, Merkt D, Kirsten D, Jorres RA, Magnussen H. Does exercise training influence daily activity of patients with COPD? Am J Respir Crit Care Med 2000; 163: A753.
23. Belza B, Steele BG, Hunziker J, Lakshminaryan S, Holt L, Buchner DM. Correlates of physical activity in chronic obstructive pulmonary disease. Nurs Res 2001; 50: 195-202.
24. Lacasse Y, Guyatt GH, Goldstein RS. The components of a respiratory rehabilitation program: a systematic overview. Chest 1997; 111: 1077-1088.
25. Normandin EA, McCusker C, Connors M, Vale F, Gerardi D, ZuWallack RL. An evaluation of two approaches to exercise conditioning in pulmonary rehabilitation. Chest 2002; 121: 1085-1091.
26. Behnke M, Schwertfeger I, von Froreich K, et al. Monitoring home-based exercise training in patients with stable COPD. Am J Respir Crit Care Med 2002; 165: A16.
27. Liesker JJW, Wijkstra PJ, Ten Hacken NHT, et al. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest 2002; 121: 597-608.
28. Disse B. Antimuscarinic treatment for lung diseases from research to clinical practice. Life Sci 2001; 68: 2257-2564.
29. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
30. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-216.
31. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
32. Ferguson GT. The ins and outs of breathing: an overview of lung mechanics. Eur Respir Rev 2004; 13: 89, 30-34.
33. O'Donnell DE. Lung mechanics in COPD: the role of tiotropium. Eur Respir Rev 2004; 13: 89, 40-44.
34. Witek TJ, Jr., Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21: 267-272.